Alethia Young
CIK 1918147 · Chief Financial Officer · last filed 2026-06-12
Alethia Young is a Chief Financial Officer who has filed 27 SEC Form 4 insider transactions across 4 companies since 2022. The most recent filing, for PCRX, was dated Jun 12, 2026. Across all open-market trades the lifetime net is −$542.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $2.4M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$2.38M
4
27
-$542.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PCRX | Director | 17,798 | $24.43 | $434.8K | $0 | 4 | 2026-06-12 |
| BCYC | Chief Financial Officer | 91,415 | $4.11 | $375.7K | -$77.4K | 7 | 2026-01-06 |
| PTCT | Director | 21,067 | $74.63 | $1.57M | -$465.0K | 6 | 2026-01-06 |
| LENZ Therapeutics, Inc. (GRPH) Delisted | Chief Financial Officer | — | $22.26 | — | $0 | 2 | 2023-02-23 |
Recent Filings
27 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-06-12 | PCRX | Grant (A) | +6,405 | $0 | EDGAR |
| 2026-04-02 | — | Notice (144) | −2,034 | -$10.0K | EDGAR |
| 2026-01-06 | BCYC | Mixed | +42,377 | -$50.5K | EDGAR |
| 2026-01-06 | PTCT | Grant (A) | +4,000 | $0 | EDGAR |
| 2026-01-05 | — | Notice (144) | −123 | -$803 | EDGAR |
| 2026-01-02 | — | Notice (144) | −7,500 | -$51.0K | EDGAR |
| 2025-10-06 | BCYC | Sell (S) | −482 | -$4.1K | EDGAR |
| 2025-10-02 | — | Notice (144) | −486 | -$3.4K | EDGAR |
| 2025-07-07 | BCYC | Sell (S) | −204 | -$1.4K | EDGAR |
| 2025-07-02 | — | Notice (144) | −206 | -$1.5K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.